A Prospective Study of Patients With Hypoplastic Left Heart Syndrome (HLHS) Following Stage II Surgical Palliation
Status: | Recruiting |
---|---|
Conditions: | Cardiology |
Therapuetic Areas: | Cardiology / Vascular Diseases |
Healthy: | No |
Age Range: | Any |
Updated: | 4/5/2019 |
Start Date: | October 2012 |
End Date: | November 2020 |
Contact: | Karen S Miller |
Email: | miller.karen1@mayo.edu |
Phone: | 507-266-5510 |
Hypoplastic left heart syndrome (HLHS) is a severe form of congenital heart disease that
consists of multiple obstructions to flow through the left heart and aorta, as well as
hypoplasia of the left ventricle. Most patients require a three-stage surgical protocol
starting within days of birth. Stage I of this process is the Norwood reconstruction (within
the first few days of life), Stage II (usually required within 3-8 months) involves creation
of a direct connection between the patient's superior vena cava and the pulmonary arterial
confluence (bidirectional Glenn anastomosis), and the last stage is creation of a Fontan
circulation (typically within the first 2-4 years). This "single ventricle" approach requires
the right ventricle to perform as the only circulatory pump for the entire body.
Our long-term goal is to develop regenerative strategies to strengthen and augment the right
ventricular muscle of the single-ventricle heart following surgical palliation in HLHS
patients. To determine the safety and feasibility of a cell-based therapeutic intervention at
the Stage II surgery, we aim to document the natural history of post-surgical care in HLHS
patients having undergone standard of care with protocol specific follow-up over the course
of a 6-month period.
This prospective study will document the natural history in patients with HLHS after planned
Stage II surgical palliation with a focus on cardiovascular parameters within 6 months
following surgery in 10 patients.
consists of multiple obstructions to flow through the left heart and aorta, as well as
hypoplasia of the left ventricle. Most patients require a three-stage surgical protocol
starting within days of birth. Stage I of this process is the Norwood reconstruction (within
the first few days of life), Stage II (usually required within 3-8 months) involves creation
of a direct connection between the patient's superior vena cava and the pulmonary arterial
confluence (bidirectional Glenn anastomosis), and the last stage is creation of a Fontan
circulation (typically within the first 2-4 years). This "single ventricle" approach requires
the right ventricle to perform as the only circulatory pump for the entire body.
Our long-term goal is to develop regenerative strategies to strengthen and augment the right
ventricular muscle of the single-ventricle heart following surgical palliation in HLHS
patients. To determine the safety and feasibility of a cell-based therapeutic intervention at
the Stage II surgery, we aim to document the natural history of post-surgical care in HLHS
patients having undergone standard of care with protocol specific follow-up over the course
of a 6-month period.
This prospective study will document the natural history in patients with HLHS after planned
Stage II surgical palliation with a focus on cardiovascular parameters within 6 months
following surgery in 10 patients.
Inclusion Criteria:
- Individuals with HLHS having undergone Stage I surgical palliation and undergoing
planned Stage II palliative Glenn surgery.
- Individuals up to 18 months of age are eligible if written informed consent can be
obtained from both parents and/or legal guardians, unless one parent is not reasonably
available.
Exclusion Criteria:
- Severe chronic diseases, extensive extra-cardiac syndromic features, or history of
cancer
The following complications of congenital heart disease:
- Any condition requiring urgent, or unplanned procedure within 15 days prior to Stage
II surgical repair.
- Severe pulmonary hypertension (reported in the medical record as >70% systemic
pressure).
- Other clinical concerns as documented by a site investigator that would predict (more
likely to happen than not to happen) a risk of severe complications or very poor
outcome during or after Stage II surgical repair.
We found this trial at
3
sites
Oklahoma City, Oklahoma 73104
Principal Investigator: Harold M Burkhart, M.D.
Phone: 405-271-8001
Click here to add this to my saved trials
South 34th Street
Philadelphia, Pennsylvania 19104
Philadelphia, Pennsylvania 19104
215-590-1000
Principal Investigator: Joseph W. Rossano, M.D.
Phone: 267-425-6614
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
Click here to add this to my saved trials
Rochester, Minnesota 55905
Principal Investigator: Muhammad Y Qureshi, MBBS
Phone: 507-266-5510
Click here to add this to my saved trials